peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GLP-1/glucagon dual agonist

Survodutide

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

Study findings

The trial’s co-primary outcomes assess continuous weight change (percent change) and a categorical threshold response (≥5% loss) over 76 weeks.

Sources[1]pubmedSurvodutide Once Weekly for the Treatment of Adults with Obesity.The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76.”

    Survodutide Once Weekly for the Treatment of Adults with Obesity. · METHODS

    pubmed:42253238:1da898b2f820:1da898b2f820

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, identity, interaction, mechanism, regulatory, safety
  • 58 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (34), assurance_score_below_0.72 (18), current_regulatory_source_required (9), extraction_ambiguity (52), high_risk_requires_regulatory_or_two_independent_sources (20), no_direct_support (50)
  • A source-backed introductory overview is not yet available.

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Survodutide Once Weekly for the Treatment of Adults with Obesity. ↗

    pubmed · published 2026-08-20 · retrieved 2026-08-29T08:37:13Z

Publication history and provenance

Version 2 · Automated assessment · 2026-09-02T08:48:30Z

fd58219e15e148661f206245c85ac8e90afb3699f3cdb472e70bf9b0399bda9c